MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:42Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Antineoplastics]]
			[[Category:Antimetabolites]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #267

2026-05-23T04:15:07Z

parser-claude batch MedTemplate pre-fill, Top 300 #267

New page

{{MedTemplate
| generic = Fluorouracil (5-FU)
| brand = Efudex (topical), Carac (topical), Fluoroplex (topical); generic IV
| structure =
| classes = [[:Category:Antineoplastics|Antineoplastic]], [[:Category:Antimetabolites|Antimetabolite (pyrimidine analog)]]
| uses = <vote slug="actinic-keratosis-use">Actinic keratosis (topical)</vote>, <vote slug="superficial-bcc-use">Superficial basal cell carcinoma (topical)</vote>, <vote slug="colorectal-cancer-use">Colorectal and other GI malignancies (IV systemic, in regimens)</vote>, <vote slug="breast-cancer-systemic-use">Breast cancer (IV, in regimens)</vote>
| starting_dose = Topical: 0.5-5% cream/solution to lesions BID × 2-4 weeks; systemic IV: regimen-specific in cancer chemotherapy
| preparations = 0.5% (Carac), 1% (Fluoroplex), 5% (Efudex) topical creams/solutions; 50 mg/mL IV
| fda_max = Topical: nightly; systemic: regimen-specific
| pill_id =
| routes = Topical, IV
| onset = Topical: inflammation, erythema, crusting at 2 weeks; complete response weeks to months after course
| duration = N/A
| halflife = ~10-20 minutes systemically (rapid hepatic and erythrocyte dihydropyrimidine dehydrogenase clearance)<ref name="efudex-label">FDA Prescribing Information, Efudex (fluorouracil) topical, Valeant/Bausch, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/016831s050lbl.pdf</ref>
| bioavailability = Topical: minimal systemic absorption (oral systemic 5-FU not used due to poor and variable absorption)<ref name="efudex-label" />
| pregnancy = Topical: avoid; systemic: contraindicated in pregnancy.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="fluorouracil-mech-claim">Fluorouracil is a fluorinated pyrimidine analog incorporated into RNA and converted to fluorodeoxyuridine monophosphate (FdUMP), which covalently inhibits thymidylate synthase and blocks de novo dTMP synthesis; the resulting "thymineless death" is most potent against rapidly dividing cells.</vote> Severe systemic toxicity (myelosuppression, mucositis, diarrhea, hand-foot syndrome, neurotoxicity in 5-10%) is amplified in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency; CPIC-supported pre-treatment DPYD genotyping is standard in many oncology centers<ref name="cpic-5fu-dpyd">CPIC Guideline for DPYD and Fluoropyrimidines, 2017 (update 2024). https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/</ref>. Topical actions reproduce the same antimetabolite effect locally with minimal systemic absorption.
}}

== References ==
<references />

Fluorouracil - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #267